Revolutionizing TB Diagnostics
Our TB diagnostic platform incorporates an innovative biophotonic detection technology that utilizes Reporter Enzyme Fluorescence (REF) to detect β-lactamase produced by live bacteria. The first application of the technology being pursued by GBD is the development of diagnostic assays that allow the sensitive and specific detection of Tuberculosis. The platform was developed by researchers at the Texas A&M Health Science Center College of Medicine, Texas A&M University and Stanford University. The conceptual research conducted by Texas A&M and Stanford was funded by the Bill and Melinda Gates Foundation.
Commercialization and product development of a point of care application of the technology is proceeding through a co-development agreement with the Foundation for Innovative New Diagnostics (FIND) based in Geneva, Switzerland.
The company owns the worldwide exclusive license to develop, manufacture and sell products that are based on the platform technology. The technology has both in vitro diagnostic and in vivo research applications.
The in vivo platform promises to provide a new, cost-effective, rapid tool for pharmaceutical companies and researchers to measure the efficacy of their experimental therapeutic compounds.